Defining intermediate-risk non-muscle-invasive bladder cancer

被引：0
|
作者：
S. Bruce Malkowicz
机构：
[1] Perelman School of Medicine,Division of Urology, Department of Surgery
[2] University of Pennsylvania,undefined
来源：
Nature Reviews Urology | 2014年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The pathology of intermediate-risk non-muscle-invasive bladder cancer is less well-defined than both high-risk and low-risk presentations of this disease. Recently reported guidelines seek to aid clinicians in classification of intermediate-risk patients, and also provide treatment recommendations for this subgroup.
引用
收藏
页码：430 / 432
页数：2
相关论文
共 50 条
  • [21] OPTIMAL SUBCLASSIFICATION SYSTEM FOR INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER
    Matsumoto, Kazuhiro
    Kikuchi, Eiji
    Yanai, Yoshinori
    Hayakawa, Nozomi
    Niwa, Naoya
    Takahiro, Maeda
    Asanuma, Hiroshi
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2019, 201 (04): : E315 - E315
  • [22] Re: Hyperthermic Mitomycin C in Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: Results of the HIVEC-1 Trial
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2023, 210 (06): : 929 - 930
  • [23] Is Intravesical Bacillus Calmette-Guerin Therapy Superior to Chemotherapy for Intermediate-risk Non-muscle-invasive Bladder Cancer? - An Ongoing Debate
    Han, Kyung-Sik
    You, Dalsan
    Jeong, In Gab
    Kwon, Teakmin
    Hong, Bumsik
    Hong, Jun Hyuk
    Ahn, Hanjong
    Ahn, Tai Young
    Kim, Choung-Soo
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (03) : 252 - 258
  • [24] Recurrence- and progression-free survival in intermediate-risk non-muscle-invasive bladder cancer: the impact of conditional evaluation and subclassification
    Kohada, Yuki
    Hayashi, Tetsutaro
    Hsi, Ryan S.
    Yukihiro, Kazuma
    Sentani, Kazuhiro
    Goto, Keisuke
    Inoue, Shogo
    Ohara, Shinya
    Teishima, Jun
    Kajiwara, Mitsuru
    Nishisaka, Takashi
    Yasui, Wataru
    Black, Peter C.
    Matsubara, Akio
    BJU INTERNATIONAL, 2021, 127 (04) : 473 - 485
  • [25] Results from HIVEC-II for Intermediate-risk Non-muscle-invasive Bladder Cancer: Is This a Dead End for Mitomycin C Hyperthermia?
    Cerrato, Clara
    Roupret, Morgan
    Mir, Maria Carmen
    EUROPEAN UROLOGY, 2023, 83 (06) : 505 - 507
  • [26] Is Office-based Management of Intermediate-risk Low-grade Non-muscle-invasive Bladder Cancer Ready For Prime Time?
    Taylor, Jacob
    Lotan, Yair
    EUROPEAN UROLOGY, 2023, 83 (02) : 131 - 132
  • [27] Bacillus Calmette-Guerin versus Mitomycin C for the Treatment of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: The Debate Continues
    Sylvester, Richard J.
    EUROPEAN UROLOGY, 2009, 56 (02) : 266 - 268
  • [28] CHARACTERIZING INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER: IMPLICATIONS FOR THE DEFINITION OF INTERMEDIATE RISK AND TREATMENT STRATEGY
    Matsumoto, Kazuhiro
    Kikuchi, Eiji
    Yanai, Yoshinori
    Hayakawa, Nozomi
    Ito, Yujiro
    Maeda, Takahiro
    Nagata, Hirohiko
    Miyajima, Akira
    Oya, Mototsugu
    JOURNAL OF UROLOGY, 2016, 195 (04): : E141 - E141
  • [29] INTRAVESICAL THERAPY IN PATIENTS WITH INTERMEDIATE-RISK NON-MUSCLE-INVASIVE BLADDER CANCER: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF ONCOLOGIC OUTCOMES
    Laukhtina, Ekaterina
    Abufaraj, Mohammad
    Al-Ani, Abdallah
    Ali, Mustafa Rami
    Mori, Keiichiro
    Moschini, Marco
    Quhal, Fahad
    Motlagh, Reza Sari
    Pradere, Benjamin
    Schuettfort, Victor M.
    Mostafaei, Hadi
    Katayama, Satoshi
    Grossmann, Nico S.
    Fajkovic, Harun
    Soria, Francesco
    Enikeev, Dmitry
    Shariat, Shahrokh F.
    JOURNAL OF UROLOGY, 2021, 206 : E1140 - E1141
  • [30] Prediction model for recurrence probabilities after intravesical chemotherapy in patients with intermediate-risk non-muscle-invasive bladder cancer, including external validation
    Lammers, Rianne J. M.
    Hendriks, Jan C. M.
    Rodriguez Faba Rodriguez Faba, O.
    Witjes, Wim P. J.
    Palou, Joan
    Witjes, J. Alfred
    WORLD JOURNAL OF UROLOGY, 2016, 34 (02) : 173 - 180
12345